HomeAI · summaries
Storia in 5 fonti
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals - Jazz Pharmaceuticals (NASDAQ:JAZZ)
FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
New Jazz cancer drug approval could drive blockbuster sales
Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
- ·
healio.com
FDA approves Ziihera combinations for gastroesophageal adenocarcinoma
The FDA approved two zanidatamab-hrii-based regimens as first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal…
